Advertisement

High serum matrix metalloproteinase-9 level predict increased risk of in-hospital cardiac events in patients with type 2 diabetes and ST segment elevation myocardial infarction

      Abstract

      Introduction

      The purpose of this study was to compare serum matrix metalloproteinase (MMP)-9 levels in a population of type 2 diabetic versus non-diabetic patients hospitalized with ST-segment elevation myocardial infarction (STEMI) and to examine the relationship between serum MMP-9 levels and the incidence of in-hospital cardiac events, including death and cardiogenic shock.

      Methods

      We recruited 120 patients with STEMI, of whom 48 were type 2 diabetic and 72 non-diabetic. Serum MMP-9 levels were measured on admission, using a commercially available ELISA. The primary study endpoint was cardiac death in-hospital and cardiogenic shock.

      Results

      Mean serum MMP-9 levels were significantly higher in type 2 diabetic patients compared to non-diabetic patients (240 ± 52 ng/mL versus 185 ± 47 ng/mL; P < 0.0001). In multivariable analysis, type 2 diabetes was an independent factor for mortality [OR: 1.75 (1.40–2.30); P = 0.005] and cardiogenic shock [OR: 1.55 (1.20–1.70); P = 0.03] when the variable MMP-9 level was not introduced into the model, but it was less significantly associated with mortality [OR: 1.60 (1.40–2.10); P = 0.01] and no longer associated with cardiogenic shock when MMP-9 was in the model.

      Conclusion

      After STEMI, type 2 diabetes is independently associated with high serum MMP-9 levels. This elevated MMP-9 is strongly associated with the increased incidence of in-hospital mortality and cardiogenic shock observed in type 2 diabetes. Our findings clearly indicate that serum MMP-9 provides a highly valuable prognostic information on in-hospital outcome after STEMI, in particular in type 2 diabetic patients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Diez J.
        Emerging role of metalloproteinases in the pathophysiology of cardiac diseases.
        Eur J Clin Invest. 2002; 32: 291-294
        • Cheung P.Y.
        • Sawicki G.
        • Wozniak M.
        • Wang W.
        • Randomski M.W.
        • Shulz R.
        Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart.
        Circulation. 2000; 101: 1833-1839
        • Lindsey M.
        • Wedin K.
        • Brown M.D.
        • et al.
        Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion.
        Circulation. 2001; 103: 2181-2187
        • Kai H.
        • Ikeda H.
        • Yasukawa H.
        • et al.
        Peripheral blood levels of matrix metalloproteases-2 and −9 are elevated in patients with acute coronary syndromes.
        J Am Coll Cardiol. 1998; 32: 368-372
        • Inokubo Y.
        • Hanada H.
        • Ishizaka H.
        • Fukushi T.
        • Kamada T.
        Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome.
        Am Heart J. 2001; 141: 211-217
        • Blankenberg S.
        • Rupprecht H.J.
        • Poirier O.
        • et al.
        Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease.
        Circulation. 2003; 107: 1579-1585
        • Garcia M.J.
        • McNamara P.M.
        • Gordon T.
        • Kannel W.B.
        Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study.
        Diabetes. 1974; 23: 105-111
        • Franklin K.
        • Goldberg R.J.
        • Spencer F.
        • et al.
        Implications of diabetes in patients with acute coronary syndromes: the Global Registry of Acute Coronary Events.
        Arch Intern Med. 2004; 164: 1457-1463
        • Marx N.
        • Froehlich J.
        • Siam L.
        • et al.
        Antidiabetic PPAP gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease.
        Arterioscler Thromb Vasc Biol. 2003; 23: 283-288
      1. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardilogy Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36:959–69.

        • Killip T.
        • Kimball J.T.
        Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients.
        Am J Cardiol. 1967; 20: 457-464
        • Wahr D.W.
        • Wang Y.S.
        • Schiller N.B.
        Left ventricular volumes determined by two-dimensional echocardiography in a normal adult population.
        J Am Coll Cardiol. 1983; 1: 863-868
        • Hasdai D.
        • Topol E.J.
        • Califf R.M.
        • Berger P.B.
        • Holmes Jr., D.R.
        Cardiogenic shock complicating acute coronary syndromes.
        Lancet. 2000; 356: 749-756
        • Fujimoto N.
        • Hosokawa N.
        • Iwata K.
        • Shinya T.
        • Okada Y.
        • Hayakama T.
        A one-step sandwich enzyme immunoassay for the inactive precursor and complexes forms of human matrix metalloprotease 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies.
        Clin Chim Acta. 1994; 231: 79-88
        • Norhammar A.
        • Tenerz A.
        • Nilsson G.
        • et al.
        Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study.
        Lancet. 2002; 359: 2140-2144
      2. American Diabetes Association. Screening for type 2 diabetes: Diabetes Care 2004;(Suppl. 1):S11–S14.

        • Hasdai D.
        • Califf R.M.
        • Thompson T.D.
        • et al.
        Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction.
        J Am Coll Cardiol. 2000; 35: 136-143
        • Granger C.B.
        • Goldberg R.J.
        • Dabbous O.
        • et al.
        Predictors of hospital mortality in the global registry of acute coronary events.
        Arch Intern Med. 2003; 163: 2345-2353
        • Abbott R.D.
        • Donahue R.P.
        • Kannel W.B.
        • Wilson P.W.
        The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study.
        JAMA. 1988; 260: 3456-3460
        • Yarom R.
        • Zirkin H.
        • Stammler G.
        • Rose A.G.
        Human coronary microvessels in diabetes and in ischaemia. Morphometric study of autopsy material.
        J Pathol. 1992; 166: 265-270
        • Landmesser U.
        • Hornig B.
        • Drexler H.
        Endothelial function: a critical determinant in atherosclerosis?.
        Circulation. 2004; 109: II27-II33
        • Stone P.H.
        • Muller J.E.
        • Hartwell T.
        • et al.
        The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group.
        J Am Coll Cardiol. 1989; 14: 49-57
        • Moreno P.R.
        • Murcia A.M.
        • Palacios I.F.
        Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus.
        Circulation. 2000; 102: 2180-2184
        • Attali J.R.
        • Sachs R.N.
        • Valensi P.
        • et al.
        Asymptomatic diabetic cardiomyopathy: a noninvasive study.
        Diabetes Res Clin Pract. 1988; 4: 421-424
        • Bouchard A.
        • Sanz N.
        • Botvinick E.H.
        • et al.
        Noninvasive assessment of cardiomyopathy in normotensive diabetic patients between 20 and 50 years old.
        Am J Med. 1989; 87: 160-166
        • Feldman A.M.
        • Li Y.Y.
        • McTiernan C.F.
        Matrix metalloproteinases in pathophysiology and treatment of heart failure.
        Lancet. 2001; 357: 654-655
        • Siwik D.A.
        • Pagano P.J.
        • Colucci W.S.
        Oxidative stress regulates collagen síntesis and matriz metalloproteinase activity in cardiac fibroblasts.
        Am J Physiol Cell Physiol. 2001; 280: 53-60
        • Wilson E.M.
        • Gunasinghe H.R.
        • Coker M.L.
        • et al.
        Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
        J Card Fail. 2001; 8: 390-398
        • Lendon C.L.
        • Davies M.J.
        • Born G.V.
        • Richardson P.D.
        Atherosclerotic plaque caps are locally weakened when macrophage density is increased.
        Atherosclerosis. 1991; 87: 87-90
        • Death A.K.
        • Fisher E.J.
        • McGrath K.C.
        • Yue D.K.
        High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes.
        Atherosclerosis. 2003; 168: 263-269
        • Portik-Dobos V.
        • Anstadt M.
        • Hutchinson J.
        • Bannan M.
        • Ergul A.
        Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes.
        Diabetes. 2002; 51: 3063-3068
        • Tayebjee M.H.
        • Lim H.S.
        • MacFayden R.J.
        • Lip G.Y.
        Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes: effect of 1 year's cardiovascular risk reduction therapy.
        Diabetes Care. 2004; 27: 2049-2051
        • Creemers E.E.
        • Cleutjens J.P.
        • Smits J.F.
        • Daemen M.J.
        Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?.
        Circ Res. 2001; 89: 201-210